Search
Assertio Holdings Inc
ASRTAdd to Watchlist
23.320USD
0.0000.00%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
150.30MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+4.29%
1 Month
+29.48%
6 Months
+107.95%
Year to Date
+157.11%
1 Year
+3402.55%
TradingKey Stock Score of Assertio Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
Assertio Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 23.87.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Assertio Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Assertio Holdings Inc Highlights
StrengthsRisks
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Undervalued
The company’s latest PE is -4.20, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.20M shares, decreasing 3.11% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 190.70K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.03.
Analyst Rating
Based on
4
analysts
Hold
Current Rating
24.433
Target Price
+4.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Assertio Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Assertio Holdings Inc Info
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Ticker SymbolASRT
CompanyAssertio Holdings Inc
CEOReisenauer (Mark L)
Websitehttps://www.assertiotx.com/
Related Instruments
-1.67%
+1.29%
+0.97%
-0.47%
+0.72%
+1.06%
-0.59%
+0.07%
-1.03%
0.00%
+0.54%
-0.08%
+1.99%
+1.19%
+2.02%
0.00%
-9.82%
-0.24%
-2.88%
+2.34%Popular Instruments
102.763
+0.307 (+0.30%)
297.840
-2.390 (-0.80%)
222.320
-3.000 (-1.33%)
4558.320
-7.800 (-0.17%)
458.680
-23.340 (-4.84%)
1333.010
-74.600 (-5.30%)
681.540
-43.120 (-5.95%)
396.940
+0.160 (+0.04%)
76937.200
+57.280 (+0.07%)
409.990
-12.250 (-2.90%)
